

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

March 14, 2025

Paul Hickey President and Chief Executive Officer ReShape Lifesciences Inc. 8 Technology Drive, Suite 110 Irvine, CA 92618

Re: ReShape Lifesciences Inc.
Preliminary Proxy Statement on Schedule 14A
Filed March 3, 2025
File No. 001-37897

Dear Paul Hickey:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Brett Hanson, Esq.